Public Employees Retirement System of Ohio Takes Position in Abbott Laboratories $ABT

Public Employees Retirement System of Ohio bought a new position in shares of Abbott Laboratories (NYSE:ABT) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 681,832 shares of the healthcare product maker’s stock, valued at approximately $61,869,000.

A number of other large investors have also added to or reduced their stakes in the business. MidAtlantic Capital Management Inc. bought a new position in Abbott Laboratories during the fourth quarter worth $25,000. Cornerstone Financial Management LLC bought a new position in shares of Abbott Laboratories in the fourth quarter valued at about $25,000. Purpose Unlimited Inc. acquired a new stake in shares of Abbott Laboratories during the 4th quarter worth about $25,000. Portfolio Resources Advisor Group Inc. bought a new stake in shares of Abbott Laboratories during the 4th quarter worth about $26,000. Finally, Abound Financial LLC acquired a new position in Abbott Laboratories in the 4th quarter valued at about $26,000. Institutional investors own 75.18% of the company’s stock.

Key Headlines Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott outperformed the market during the latest trading session, supported by continued investor interest in the diversified healthcare-products maker. Its shares are trading above both the 50-day and 200-day moving averages, indicating favorable near-term momentum. Abbott Exceeds Market Returns: Some Facts to Consider
• Positive Sentiment: Abbott’s latest reported quarter showed solid fundamentals: adjusted earnings exceeded consensus estimates, revenue surpassed expectations, and sales increased 13% year over year. Management’s 2026 earnings guidance remains consistent with analyst expectations, helping support the investment case.
• Neutral Sentiment: Industry research projects continued growth in cardiovascular ultrasound systems through 2030, driven by portable devices, artificial intelligence, 3D/Doppler imaging and remote diagnostics. The opportunity is broadly relevant to Abbott’s cardiovascular-device business, although the report primarily highlights GE HealthCare, Philips and Siemens Healthineers rather than announcing a specific Abbott development. Cardiovascular Ultrasound Systems Market Outlook
• Neutral Sentiment: Recent commentary notes that Abbott has lagged the healthcare sector over the past year, but analysts remain broadly optimistic about its long-term prospects. This creates a mixed backdrop: valuation and relative performance could restrain gains, while analyst confidence and business diversification provide support. Abbott Laboratories Stock: Is ABT Underperforming the Healthcare Sector?

Abbott Laboratories Trading Up 1.5%

ABT opened at $110.52 on Thursday. The stock has a market capitalization of $191.24 billion, a price-to-earnings ratio of 35.77, a P/E/G ratio of 2.02 and a beta of 0.59. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. Abbott Laboratories has a twelve month low of $81.97 and a twelve month high of $137.49. The company has a 50-day simple moving average of $103.83 and a 200 day simple moving average of $100.09.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, beating the consensus estimate of $1.28 by $0.03. The firm had revenue of $12.59 billion for the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The business’s quarterly revenue was up 13.0% compared to the same quarter last year. During the same period last year, the firm earned $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Analysts predict that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th were given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 2.3%. The ex-dividend date was Wednesday, July 15th. Abbott Laboratories’s payout ratio is currently 81.55%.

Analysts Set New Price Targets

ABT has been the subject of several research reports. TD Cowen raised their price objective on shares of Abbott Laboratories from $115.00 to $135.00 and gave the stock a “buy” rating in a research report on Tuesday, August 25th. Bank of America decreased their target price on Abbott Laboratories from $120.00 to $102.00 in a research report on Friday, June 12th. Weiss Ratings upgraded Abbott Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, August 6th. Wells Fargo & Company boosted their price target on Abbott Laboratories from $109.00 to $112.00 and gave the company an “overweight” rating in a research note on Friday, July 17th. Finally, Wolfe Research raised Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 price objective on the stock in a report on Thursday, August 13th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $119.50.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.